Drug Design, Development and Therapy (Sep 2015)

Decreased expression of the APOA1–APOC3–APOA4 gene cluster is associated with risk of Alzheimer’s disease

  • Lin Q,
  • Cao Y,
  • Gao J

Journal volume & issue
Vol. 2015, no. default
pp. 5421 – 5431

Abstract

Read online

Qiao Lin,1 Yunpeng Cao,2 Jie Gao3 1Department of Internal Medicine, Fourth Affiliated Hospital of China Medical University, 2Neural Department of Internal Medicine, 3Department of Anatomy, First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of China Background: Apolipoprotein is genetically associated with the risk of Alzheimer’s disease (AD). The APOA1, APOC3, and APOA4 genes are closely linked and located on human chromosome 11. Therefore, this gene cluster may be related to the risk of AD.Patients and methods: A total of 147 AD patients and 160 healthy controls were randomly recruited from June 2013 to August 2014. APOA1, APOC3, and APOA4 levels were measured using real-time quantitative reverse-transcriptase polymerase chain reaction and enzyme-linked immunosorbent assay.Results: APOA1, APOC3 and APOA4 levels were significantly lower in AD patients than controls (P<0.01). APOA1, APOC3, and APOA4 levels were negatively related with the severities of AD determined by Clinical Dementia Rating scores (P<0.01). APOA1, APOC3, and APOA4 levels showed a negative relation with Montgomery–Åsberg Depression Rating Scale scores and a positive relation with RAND 36-item health-survey scores (P<0.01). There was a decreased trend for levels of APOA1, APOC3, and APOA4 in AD patients.Conclusion: Low levels of APOA1, APOC3, and APOA4 are associated with risk of AD. APOA1, APOC3, and APOA4 should be developed as combined drugs for the therapy of AD. Keywords: Alzheimer’s disease, APOA1–APOC3–APOA4 gene cluster, enzyme-linked immunosorbent assay, Montgomery–Åsberg Depression Rating Scale, RAND 36-item health survey, real-time quantitative reverse-transcriptase PCR